公开(公告)号：US20150080447A1

公开(公告)日：2015-03-19

申请号：US14331962

申请日：2014-07-15

申请人： H. L. Hall & Sons Limited

发明人： Nigel Gericke ,  Alan Harvey ,  Alvaro Viljoen ,  Deon Hofmeyr

IPC分类号： A61K36/185 ,  A61K31/403

CPC分类号： A61K36/185 ,  A61K31/403

摘要： A composition including as an active ingredient an extract of a plant of the family Mesembryanthemaceae with mesembrenol and mesembrenone as the two major alkaloids present. The invention also relates to the use of the composition as a PDE4 inhibitor and as a serotonin-uptake inhibitor, preferably applied in formulations for the use of the composition as a dual serotonin-uptake inhibitor and PDE4 inhibitor. The invention extends to compositions, such as pharmaceutical compositions or compositions used as dietary supplements, the total alkaloid content of which includes at least 80% (w/w) combined content of mesembrenol and mesembrenone, less than 5% (w/w) mesembrine, and at least 7% (w/w) mesembranol.

摘要翻译： 作为活性成分的组合物，作为两种主要的生物碱，以Mesembrenol和mesembrenone为家族Mesembryanthemaceae植物的提取物。 本发明还涉及组合物作为PDE4抑制剂和5-羟色胺摄取抑制剂的用途，优选用于将组合物用作双重5-羟色胺摄取抑制剂和PDE4抑制剂的制剂中。 本发明延伸到组合物，例如用作膳食补充剂的药物组合物或组合物，其总生物碱含量包括至少80％（w / w）的联合肾上腺素和mesembrenone的组合含量，小于5％（w / w）的mesembrine ，和至少7％（w / w）的间叶吗啉。

公开(公告)号：US09381220B2

公开(公告)日：2016-07-05

申请号：US14331962

申请日：2014-07-15

申请人： H. L. Hall & Sons Limited

发明人： Nigel Gericke ,  Alan Harvey ,  Alvaro Viljoen ,  Deon Hofmeyr

IPC分类号： A61K36/185 ,  A61K36/40 ,  C07D209/32 ,  A61K31/403

CPC分类号： A61K36/185 ,  A61K31/403

摘要： A composition including as an active ingredient an extract of a plant of the family Mesembryanthemaceae with mesembrenol and mesembrenone as the two major alkaloids present. The invention also relates to the use of the composition as a PDE4 inhibitor and as a serotonin-uptake inhibitor, preferably applied in formulations for the use of the composition as a dual serotonin-uptake inhibitor and PDE4 inhibitor. The invention extends to compositions, such as pharmaceutical compositions or compositions used as dietary supplements, the total alkaloid content of which includes at least 80% (w/w) combined content of mesembrenol and mesembrenone, less than 5% (w/w) mesembrine, and at least 7% (w/w) mesembranol.